Your browser doesn't support javascript.
loading
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell, Rafael; Dafni, Urania; Felip, Enriqueta; Curioni-Fontecedro, Alessandra; Gautschi, Oliver; Peters, Solange; Massutí, Bartomeu; Palmero, Ramon; Aix, Santiago Ponce; Carcereny, Enric; Früh, Martin; Pless, Miklos; Popat, Sanjay; Kotsakis, Athanasios; Cuffe, Sinead; Bidoli, Paolo; Favaretto, Adolfo; Froesch, Patrizia; Reguart, Noemí; Puente, Javier; Coate, Linda; Barlesi, Fabrice; Rauch, Daniel; Thomas, Michael; Camps, Carlos; Gómez-Codina, Jose; Majem, Margarita; Porta, Rut; Shah, Riyaz; Hanrahan, Emer; Kammler, Roswitha; Ruepp, Barbara; Rabaglio, Manuela; Kassapian, Marie; Karachaliou, Niki; Tam, Rachel; Shames, David S; Molina-Vila, Miguel A; Stahel, Rolf A.
Afiliación
  • Rosell R; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Dafni U; Frontier Science Foundation-Hellas & National and Kapodistrian University of Athens, Athens, Greece.
  • Felip E; Vall d'Hebron University Hospital, Institute of Oncology, Barcelona, Spain.
  • Curioni-Fontecedro A; University Hospital Zurich, Clinic of Oncology, Zurich, Switzerland; Swiss Group of Clinical Cancer Research, Bern, Switzerland.
  • Gautschi O; Cantonal Hospital Lucerne, Medical Oncology, Lucerne, Switzerland; Swiss Group of Clinical Cancer Research, Bern, Switzerland.
  • Peters S; Centre Hospitalier Universitaire Vaudois, Département d'Oncologie, Lausanne, Switzerland; Swiss Group of Clinical Cancer Research, Bern, Switzerland.
  • Massutí B; Hospital General Universitario Alicante, Oncología Médica, Alicante, Spain.
  • Palmero R; Catalan Institute of Oncology, Hospital Duran i Reynals, Bellvitge, Spain.
  • Aix SP; Hospital Universitario 12 de Octubre, Oncología Médica, Madrid, Spain.
  • Carcereny E; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Früh M; Cantonal Hospital St Gallen, Oncology and Hematology, St Gallen, Switzerland; Swiss Group of Clinical Cancer Research, Bern, Switzerland.
  • Pless M; Cantonal Hospital Winterthur, Medical Oncology, Winterthur, Switzerland; Swiss Group of Clinical Cancer Research, Bern, Switzerland.
  • Popat S; Medical Oncology, Royal Marsden Hospital, London, UK.
  • Kotsakis A; University General Hospital of Heraklion, Medical Oncology, Heraklion, Crete, Greece.
  • Cuffe S; Cancer Trials Ireland and St James's Hospital, Medical Oncology, Dublin, Ireland.
  • Bidoli P; Ospedale San Gerardo, Oncologia Medica, Monza, Italy.
  • Favaretto A; Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Froesch P; Instituto Oncologica Della Svizzera Italiana, Bellinzona, Switzerland; Swiss Group of Clinical Cancer Research, Bern, Switzerland.
  • Reguart N; Hospital Clínic, Medical Oncology & Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Puente J; Thoracic, Urologic & Melanoma Cancer Unit Medical Oncology Department Hospital Clinico Universitario San Carlos, Madrid, Spain.
  • Coate L; University Hospital Limerick and Cancer Trials Ireland, Limerick, Ireland.
  • Barlesi F; Aix Marseille University; Assistance Publique Hôpitaux de Marseille, Marseille, France.
  • Rauch D; Okologiezentrum Thun-Berner Oberland, Thun, Switzerland; Swiss Group of Clinical Cancer Research, Bern, Switzerland.
  • Thomas M; Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany.
  • Camps C; University Hospital Valencia, Valencia, Spain.
  • Gómez-Codina J; Hospital La Fe, Valencia, Spain.
  • Majem M; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Porta R; Insitut Catalan d'Oncologia and University of Girona, Girona, Spain.
  • Shah R; Kent Oncology Centre, Maidstone, UK.
  • Hanrahan E; Cancer Trials Ireland and St Vincent's University Hospital, Dublin, Ireland.
  • Kammler R; European Thoracic Oncology Platform Coordinating Office, Bern, Switzerland.
  • Ruepp B; European Thoracic Oncology Platform Coordinating Office, Bern, Switzerland.
  • Rabaglio M; European Thoracic Oncology Platform Coordinating Office, Bern, Switzerland.
  • Kassapian M; Frontier Science Foundation-Hellas, Athens, Greece.
  • Karachaliou N; Institute of Oncology Rosell, University Hospital Sagrat Cor, Barcelona, Spain.
  • Tam R; Oncology Biomarker Development, Genentech, South San Francisco, CA, USA.
  • Shames DS; Oncology Biomarker Development, Genentech, South San Francisco, CA, USA.
  • Molina-Vila MA; Pangaea Biotech S L, Quirón Dexeus University Hospital, Barcelona, Spain.
  • Stahel RA; University Hospital Zurich, Clinic of Oncology, Zurich, Switzerland; Swiss Group of Clinical Cancer Research, Bern, Switzerland. Electronic address: rolf.stahel@usz.ch.
Lancet Respir Med ; 5(5): 435-444, 2017 05.
Article en En | MEDLINE | ID: mdl-28408243
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Receptores ErbB / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Respir Med Año: 2017 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Receptores ErbB / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Respir Med Año: 2017 Tipo del documento: Article País de afiliación: España